BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abou-El-Enein M, Bauer G, Reinke P. The business case for cell and gene therapies. Nat Biotechnol. 2014;32:1192-1193. [PMID: 25489833 DOI: 10.1038/nbt.3084] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Kavianpour M, Saleh M, Verdi J. The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm. Stem Cell Res Ther 2020;11:404. [PMID: 32948252 DOI: 10.1186/s13287-020-01849-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
2 Gomes-Silva D, Ramos CA. Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line. Biotechnol J 2018;13. [PMID: 28960810 DOI: 10.1002/biot.201700097] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
3 Abou-El-Enein M, Bauer G, Reinke P. Gene therapy: a possible future standard for HIV care. Trends Biotechnol 2015;33:374-6. [PMID: 26088914 DOI: 10.1016/j.tibtech.2015.03.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
4 Tran R, Myers DR, Denning G, Shields JE, Lytle AM, Alrowais H, Qiu Y, Sakurai Y, Li WC, Brand O, Le Doux JM, Spencer HT, Doering CB, Lam WA. Microfluidic Transduction Harnesses Mass Transport Principles to Enhance Gene Transfer Efficiency. Mol Ther 2017;25:2372-82. [PMID: 28780274 DOI: 10.1016/j.ymthe.2017.07.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
5 Abou-El-Enein M, Elsanhoury A, Reinke P. Overcoming Challenges Facing Advanced Therapies in the EU Market. Cell Stem Cell. 2016;19:293-297. [PMID: 27588746 DOI: 10.1016/j.stem.2016.08.012] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 18.3] [Reference Citation Analysis]
6 Bauer G, Abou-El-Enein M, Kent A, Poole B, Forte M. The path to successful commercialization of cell and gene therapies: empowering patient advocates. Cytotherapy 2017;19:293-8. [PMID: 27956199 DOI: 10.1016/j.jcyt.2016.10.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
7 Qiu T, Wang Y, Liang S, Han R, Toumi M. The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects. Drug Discov Today 2021:S1359-6446(21)00207-5. [PMID: 33892148 DOI: 10.1016/j.drudis.2021.04.020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ducret M, Fabre H, Degoul O, Atzeni G, McGuckin C, Forraz N, Alliot-Licht B, Mallein-Gerin F, Perrier-Groult E, Farges JC. Manufacturing of dental pulp cell-based products from human third molars: current strategies and future investigations. Front Physiol 2015;6:213. [PMID: 26300779 DOI: 10.3389/fphys.2015.00213] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
9 Shukla V, Seoane-Vazquez E, Fawaz S, Brown L, Rodriguez-Monguio R. The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost. Hum Gene Ther Clin Dev 2019;30:102-13. [PMID: 30968714 DOI: 10.1089/humc.2018.201] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 12.5] [Reference Citation Analysis]
10 Ylä-Herttuala S. Glybera's second act: the curtain rises on the high cost of therapy. Mol Ther 2015;23:217-8. [PMID: 25633169 DOI: 10.1038/mt.2014.248] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 6.2] [Reference Citation Analysis]
11 Childs PG, Reid S, Salmeron-Sanchez M, Dalby MJ. Hurdles to uptake of mesenchymal stem cells and their progenitors in therapeutic products. Biochem J 2020;477:3349-66. [PMID: 32941644 DOI: 10.1042/BCJ20190382] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Moll G, Drzeniek N, Kamhieh-Milz J, Geissler S, Volk HD, Reinke P. MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy. Front Immunol. 2020;11:1091. [PMID: 32574263 DOI: 10.3389/fimmu.2020.01091] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 47.0] [Reference Citation Analysis]
13 Abou-El-Enein M, Duda GN, Gruskin EA, Grainger DW. Strategies for Derisking Translational Processes for Biomedical Technologies. Trends Biotechnol 2017;35:100-8. [PMID: 27499276 DOI: 10.1016/j.tibtech.2016.07.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
14 Abou-El-Enein M, Grainger DW, Kili S. Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence. Mol Ther 2018;26:1172-6. [PMID: 29685384 DOI: 10.1016/j.ymthe.2018.04.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
15 Abou-El-Enein M, Bauer G, Medcalf N, Volk HD, Reinke P. Putting a price tag on novel autologous cellular therapies. Cytotherapy. 2016;18:1056-1061. [PMID: 27288308 DOI: 10.1016/j.jcyt.2016.05.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
16 Foldvari M, Chen DW, Nafissi N, Calderon D, Narsineni L, Rafiee A. Non-viral gene therapy: Gains and challenges of non-invasive administration methods. J Control Release 2016;240:165-90. [PMID: 26686079 DOI: 10.1016/j.jconrel.2015.12.012] [Cited by in Crossref: 119] [Cited by in F6Publishing: 93] [Article Influence: 19.8] [Reference Citation Analysis]